Innovent Biologics Inc (STU:6IB) Stock Price, Trades & News

Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	6.48
Equity-to-Asset	0.52
Debt-to-Equity	0.15
Debt-to-EBITDA	1.87
Interest Coverage	26.94
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.98	Distress Grey Safe
Beneish M-Score	-3.13	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	34.6
	3-Year Book Growth Rate	16.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	78.07
	Future 3-5Y Total Revenue Growth Rate Estimate	26.51

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	44.23
	9-Day RSI	52.68
	14-Day RSI	55.02
	3-1 Month Momentum %	-16.72
	6-1 Month Momentum %	-16.51
	12-1 Month Momentum %	-15.21

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.62
	Quick Ratio	2.47
	Cash Ratio	2.17
	Days Inventory	223.7
	Days Sales Outstanding	42.77
	Days Payable	88.3

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-4.2
	Shareholder Yield %	-3.43

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	86.54
	Operating Margin %	16.39
	Net Margin %	6.2
	EBITDA Margin %	11.61
	FCF Margin %	71.58
	OCF Margin %	76.82
	ROE %	5.21
	ROA %	2.96
	ROIC %	12.48
	3-Year ROIIC %	35.11
	ROC (Joel Greenblatt) %	17.06
	ROCE %	4.26
	Years of Profitability over Past 10-Year	1
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	176.84
	Forward PE Ratio	60.96
	PE Ratio without NRI	180.43
	Price-to-Owner-Earnings	16.8
	PS Ratio	10.75
	PB Ratio	7.22
	Price-to-Tangible-Book	8.01
	Price-to-Free-Cash-Flow	15.27
	Price-to-Operating-Cash-Flow	14.22
	EV-to-EBIT	136.59
	EV-to-Forward-EBIT	68.52
	EV-to-EBITDA	82.34
	EV-to-Forward-EBITDA	58.49
	EV-to-Revenue	9.56
	EV-to-Forward-Revenue	7.13
	EV-to-FCF	13.32
	Price-to-GF-Value	0.87
	Price-to-Projected-FCF	15.89
	Price-to-Graham-Number	8.01
	Price-to-Net-Current-Asset-Value	34.61
	Price-to-Net-Cash	484.6
	Earnings Yield (Greenblatt) %	0.73
	FCF Yield %	6.65

Financials (Next Earnings Date:2026-08-27 Est.)

Annual Quarterly TTM

STU:6IB's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Innovent Biologics Inc Executives

Details

GF Value™: €11.18

STU:6IB

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 6IB. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	1,578.292
	EPS (TTM) (€)	0.055
	Beta	-0.072
	3-Year Sharpe Ratio	0.85
	3-Year Sortino Ratio	1.52
	Volatility %	40.75
	14-Day RSI	55.02
	14-Day ATR (€)	0.387869
	20-Day SMA (€)	9.30225
	12-1 Month Momentum %	-15.21
	52-Week Range (€)	7.818 - 11.5
	Shares Outstanding (Mil)	1,740.92

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Innovent Biologics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Innovent Biologics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings results for 2026	2026-08-27	In 39 days
General meeting for 2025	2026-06-24 08:30	8.32 (+0.25%)
Annual report for 2025	2026-04-28	9.04 (+1.23%)
Fourth quarter earnings results for 2025	2026-03-26	9.05 (+2.26%)
Second quarter earnings results for 2025	2025-08-27	10.20 (+0.00%)
General meeting for 2024	2025-06-25 09:30	9.15 (+5.78%)
Annual report for 2024	2025-04-28	6.05 (+0.00%)
Fourth quarter earnings results for 2024	2025-03-26	4.54 (+0.00%)
Guidance call for 2025	2025-01-16 08:30	4.10 (+0.00%)
Second quarter earnings results for 2024	2024-08-28	4.98 (+0.00%)

Show

Entries

Innovent Biologics Inc Frequently Asked Questions

What is Innovent Biologics Inc(STU:6IB)'s stock price today?

The current price of STU:6IB is €9.69. The 52 week high of STU:6IB is €11.50 and 52 week low is €7.82.

When is next earnings date of Innovent Biologics Inc(STU:6IB)?

The next earnings date of Innovent Biologics Inc(STU:6IB) is 2026-08-27 Est..

Does Innovent Biologics Inc(STU:6IB) pay dividends? If so, how much?

Innovent Biologics Inc(STU:6IB) does not pay dividend.

Press Release

	Subject	Date
	Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma	2025-07-16
	Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms	2025-06-30
	Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management	2025-06-27
	Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions	2025-06-24
	Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions	2025-06-21
	/C O R R E C T I O N -- Innovent Biologics/	2025-06-15
	Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China	2025-06-15
	Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions	2025-06-12
	Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer	2025-06-04
	Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma	2025-06-04

10/Page

Articles on Innovent Biologics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.